Long Focus Capital Management LLC Raises Stock Position in Cellectis S.A. $CLLS

Key Points

• Long Focus Capital Management LLC increased its stake in Cellectis S.A. by 2.2%, now owning 4,717,293 shares valued at approximately $5.85 million.
• Analysts have downgraded Cellectis' stock rating, with Barclays reducing its target price from $5.00 to $4.00 and Wall Street Zen moving from a "hold" to a "sell" rating.
• Cellectis reported negative earnings of ($0.24) per share for the last quarter, missing expectations, but had revenues of $18.19 million, exceeding estimates.

Long Focus Capital Management LLC grew its holdings in shares of Cellectis S.A. (NASDAQ:CLLS - Free Report) by 2.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,717,293 shares of the biotechnology company's stock after buying an additional 100,000 shares during the quarter. Long Focus Capital Management LLC owned 8.49% of Cellectis worth $5,849,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its holdings in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares during the last quarter. OLD Mission Capital LLC bought a new position in Cellectis during the 1st quarter valued at about $31,000. Finally, Millennium Management LLC bought a new position in Cellectis during the 4th quarter valued at about $962,000. 63.90% of the stock is currently owned by institutional investors.

Cellectis Stock Performance

Shares of NASDAQ CLLS traded down $0.01 during midday trading on Thursday, reaching $2.59. The company had a trading volume of 35,432 shares, compared to its average volume of 217,630. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.58. The business's 50-day simple moving average is $2.31 and its 200 day simple moving average is $1.72. Cellectis S.A. has a 1 year low of $1.10 and a 1 year high of $3.24. The stock has a market cap of $143.67 million, a P/E ratio of -3.15 and a beta of 3.03.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%.The business had revenue of $18.19 million for the quarter, compared to analysts' expectations of $10.07 million. On average, analysts forecast that Cellectis S.A. will post -0.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Barclays cut their price target on shares of Cellectis from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Cellectis from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $4.00.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.